Cargando…

Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy

Bacteria and their derivatives (membrane vesicles, MVs) exhibit great advantages for targeting hypoxic tumor cores, strong penetration ability and activating immune responses, holding great potential as auspicious candidates for therapeutic and drug-delivery applications. However, the safety issues...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zixuan, Liang, Lizhen, Lu, Huazhen, Shen, Yan, Zhou, Wenwu, Li, Yanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684392/
https://www.ncbi.nlm.nih.gov/pubmed/34934313
http://dx.doi.org/10.2147/IJN.S329855
_version_ 1784617609785769984
author Ye, Zixuan
Liang, Lizhen
Lu, Huazhen
Shen, Yan
Zhou, Wenwu
Li, Yanan
author_facet Ye, Zixuan
Liang, Lizhen
Lu, Huazhen
Shen, Yan
Zhou, Wenwu
Li, Yanan
author_sort Ye, Zixuan
collection PubMed
description Bacteria and their derivatives (membrane vesicles, MVs) exhibit great advantages for targeting hypoxic tumor cores, strong penetration ability and activating immune responses, holding great potential as auspicious candidates for therapeutic and drug-delivery applications. However, the safety issues and low therapeutic efficiency by single administration still need to be solved. To further optimize their performance and to utilize their natural abilities, scientists have strived to modify bacteria with new moieties on their surface while preserving their advantages. The aim of this review is to give a comprehensive overview of a non-genetic engineering modification strategy that can be used to optimize the bacteria with nanomaterials and the design strategy that can be used to optimize MVs for better targeted therapy. Here, the advantages and disadvantages of these processes and their applicability for the development of bacteria-related delivery system as antitumor therapeutic agents are discussed. The prospect and the challenges of the above targeted delivery system are also proposed.
format Online
Article
Text
id pubmed-8684392
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86843922021-12-20 Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy Ye, Zixuan Liang, Lizhen Lu, Huazhen Shen, Yan Zhou, Wenwu Li, Yanan Int J Nanomedicine Review Bacteria and their derivatives (membrane vesicles, MVs) exhibit great advantages for targeting hypoxic tumor cores, strong penetration ability and activating immune responses, holding great potential as auspicious candidates for therapeutic and drug-delivery applications. However, the safety issues and low therapeutic efficiency by single administration still need to be solved. To further optimize their performance and to utilize their natural abilities, scientists have strived to modify bacteria with new moieties on their surface while preserving their advantages. The aim of this review is to give a comprehensive overview of a non-genetic engineering modification strategy that can be used to optimize the bacteria with nanomaterials and the design strategy that can be used to optimize MVs for better targeted therapy. Here, the advantages and disadvantages of these processes and their applicability for the development of bacteria-related delivery system as antitumor therapeutic agents are discussed. The prospect and the challenges of the above targeted delivery system are also proposed. Dove 2021-12-14 /pmc/articles/PMC8684392/ /pubmed/34934313 http://dx.doi.org/10.2147/IJN.S329855 Text en © 2021 Ye et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Ye, Zixuan
Liang, Lizhen
Lu, Huazhen
Shen, Yan
Zhou, Wenwu
Li, Yanan
Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy
title Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy
title_full Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy
title_fullStr Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy
title_full_unstemmed Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy
title_short Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy
title_sort nanotechnology-employed bacteria-based delivery strategy for enhanced anticancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684392/
https://www.ncbi.nlm.nih.gov/pubmed/34934313
http://dx.doi.org/10.2147/IJN.S329855
work_keys_str_mv AT yezixuan nanotechnologyemployedbacteriabaseddeliverystrategyforenhancedanticancertherapy
AT lianglizhen nanotechnologyemployedbacteriabaseddeliverystrategyforenhancedanticancertherapy
AT luhuazhen nanotechnologyemployedbacteriabaseddeliverystrategyforenhancedanticancertherapy
AT shenyan nanotechnologyemployedbacteriabaseddeliverystrategyforenhancedanticancertherapy
AT zhouwenwu nanotechnologyemployedbacteriabaseddeliverystrategyforenhancedanticancertherapy
AT liyanan nanotechnologyemployedbacteriabaseddeliverystrategyforenhancedanticancertherapy